{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T07:09:34Z","timestamp":1769756974912,"version":"3.49.0"},"reference-count":27,"publisher":"Korean Association of Internal Medicine","issue":"5","license":[{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2015R1A3A2032927"],"award-info":[{"award-number":["2015R1A3A2032927"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kjim.org"],"crossmark-restriction":true},"short-container-title":["Korean J Intern Med"],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:p>Background\/Aims: The aim of this study was to compare the short- and long-term retention rates of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b\/tsDMARDs) in Korean patients with seropositive rheumatoid arthritis.Methods: This study was conducted with 1,538 treatment courses of 1,063 patients, including adalimumab (n = 332), etanercept (n = 369), infliximab (n = 146), abatacept (n = 152), tocilizumab (n = 299), tofacitinib (n = 136), and baricitinib (n = 104), in patients with seropositive rheumatoid arthritis who started b\/tsDMARD treatment between 2008 and 2020 at Seoul St. Mary\u2019s Hospital. Discontinuation 1 and 3 years after the first prescription of each drug was investigated. Kaplan\u2013 Meier estimates of time to discontinuation were calculated to compare the difference in drug retention rate for each drug. Patient-level predictors of drug discontinuation were evaluated using a Cox proportional hazards model.Results: The overall 1-year drug retention rate was from 60.1% for adalimumab to 90.0% for tofacitinib in the b\/tsDMARD-na\u00efve group, and from 55.2% for infliximab to 84.8% for tofacitinib in the b\/tsDMARD-experienced group. The 3-year drug retention rate was from 36.9% for infliximab to 86.5% for tofacitinib in the b\/tsDMARD-na\u00efve group, and from 31.0% for infliximab to 65.4% for tocilizumab in the b\/tsDMARD-experienced group. Drug discontinuation appeared to be affected by specific types of b\/tsDMARDs.Conclusions: Tocilizumab and tofacitinib are less commonly discontinued compared to tumor necrosis factor-\u03b1 inhibitors at 1 and 3 years. Specifically, tofacitinib in the b\/tsDMARD-na\u00efve group and tocilizumab in the b\/tsDMARD-experienced group showed the highest 3-year retention rates.<\/jats:p>","DOI":"10.3904\/kjim.2023.297","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T06:07:37Z","timestamp":1716790057000},"page":"833-844","update-policy":"https:\/\/doi.org\/10.3904\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis"],"prefix":"10.3904","volume":"39","author":[{"given":"Bong-Woo","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer Jooha","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8224-8496","authenticated-orcid":true,"given":"Wan-Uk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2270","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24463"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22788"},{"key":"ref3","first-page":"1","volume-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","author":"Singh","year":"2016"},{"key":"ref4","first-page":"685","volume-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","author":"Smolen","year":"2020"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key339"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1202117"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2016.1189826"},{"key":"ref8","first-page":"837","volume-title":"TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice","author":"Marchesoni","year":"2009"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111125"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200882"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/6fcyza"},{"key":"ref12","first-page":"11091","volume-title":"Clinical factors associated with discontinuation of ts\/bDMARDs in rheumatic patients from the BIOBADASER III registry","author":"Prior-Espa\u00f1ol","year":"2021"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2147\/ppa.s110147"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02232-w"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.06.002"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev019"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175207"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202545"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0231-8"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202220"},{"key":"ref21","first-page":"18","volume-title":"Maintenance and tolerability of infliximab in a cohort of 152 patients with rheumatoid arthritis","author":"Figueiredo","year":"2008"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2109927"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez087"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/art.40189"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001892"},{"key":"ref26","first-page":"3","volume-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","author":"Smolen","year":"2023"},{"key":"ref27","first-page":"31","volume-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","author":"Nagy","year":"2021"}],"container-title":["The Korean Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.kjim.org\/upload\/kjim-2023-297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.kjim.org\/journal\/view.php?doi=10.3904\/kjim.2023.297","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.kjim.org\/upload\/kjim-2023-297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T06:44:11Z","timestamp":1725605051000},"score":1,"resource":{"primary":{"URL":"http:\/\/kjim.org\/journal\/view.php?doi=10.3904\/kjim.2023.297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"URL":"https:\/\/doi.org\/10.3904\/kjim.2023.297","relation":{},"ISSN":["1226-3303","2005-6648"],"issn-type":[{"value":"1226-3303","type":"print"},{"value":"2005-6648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,1]]},"assertion":[{"value":"2023-07-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-27","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-01","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}